Browsing items tagged “Oncology | EVERSANA”

Just Half of Germany’s Clinical Cancer Registries Fully Operational at the End of Last Year

Country: GERMANY | Region: EUROPE | Type: Policy | Keywords: #cancer #germany #gkv-sv #insurance #operational #registry PRICENTRIC BRIEF: The National Association of Statutory Health Insurance Funds, GKV-Spitzenverband (GKV-SV), has noted that at the end of 2019, just under half of Germany’s clinical cancer registries were fully operational At the cut-off, December 31, the group says that just four – Baden-Württemberg, Bremen, Rhineland-Palatinate, Saarland – met eligibility criteria for the health insurances […]

Fiocruz Produces Breast Cancer Drug Trastuzumab for Brazil’s SUS

 Country: BRAZIL | Region: SOUTH AMERICA | Type: Pricing & Reimbursement | Keywords: #bio-manguinhos #breastcancer #fiocruz #oncology #sus #trastuzumab PRICENTRIC BRIEF: The Oswaldo Cruz Foundation is now supplying trastuzumab to the Ministry of Health (MoH), which distributes the drug to patients free of charge through the Brazilian Public Health System (SUS) to treat a subtype of breast cancer identified by the overexpression of the […]

ASEAN Joint Assessment Procedure Prioritizes 11 Diseases

Region: ASIA & SOUTH PACIFIC | Type: HTA | Keywords: #access #aids #asean #breastcancer #chronicillnesses #depression #drugapprovals #hiv #jointassessment #lungcancer #nationalmedicinesregulatoryauthorities #nra #oncology #regulation PRICENTRIC BRIEF: The National Medicines Regulatory Authorities (NRA) of the Association of Southeast Asian Nations (ASEAN) has developed a new procedure for joint marketing authorizations, the ASEAN Joint Assessment Procedure Now that the pilot, which was kicked off in July 2017 and advised technically by the World […]

Deciphera’s Qinlock Approved for Fourth-Line GIST Treatment by FDA

Country: UNITED STATES | Region: NORTH AMERICA | Type: Drug Approval | Keywords: #deciphera #fda #projectorbis #qinlock #realtimeoncologyreview PRICENTRIC BRIEF: The Food and Drug Administration (FDA) approved Deciphera’s Qinlock (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib (branded as “Gleevec” by Novartis in the U.S.) The New Drug Application (NDA) […]

Italy’s Oncological Association Seeks to Reduce Cost of CAR-T Cells

Country: ITALY | Region: EUROPE | Type: Policy | Keywords: #alleanzaagainstcancer #car-t #oncology PRICENTRIC BRIEF: Italy’s oncological association, Alleanza Against Cancer (ACC), is seeking to collaborate with the pharma industry in order to implement production capacities and harmonize and automate processes, thus reducing costs related to the manufacture of CAR-T cells The ACC’s statement said, “Indeed, a potential virtuous synergy between academic institutions and pharmaceutical industries […]

FDA OK’s AZ & Merck’s Lynparza Plus Bevacizumab in HRD-Positive Ovarian Cancer

Country: UNITED STATES | Region: NORTH AMERICA | Type: Drug Approval | Keywords: #astrazeneca #fda #merck PRICENTRIC BRIEF: Lynparza (olaparib) in combination with bevacizumab (branded as Avastin) was approved by the US Food and Drug Administration (FDA) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and […]

Biosimilars Saved Spain 2,400 Million Euros Between 2009 and 2020

Country: SPAIN | Region: EUROPE | Type: Biosimilar | Keywords: #inflammatorydiseases #monoclonalantibodies #oncology #regulation #sefh PRICENTRIC BRIEF: The Spanish Society of Hospital Pharmacists (SEFH) calculated that Spain has saved more than 2,400 million euros between 2009 and 2020 through the introduction of biosimilars for the treatment of inflammatory diseases and cancer In the article, published in the May/June issue of the journal Farmacia Hospitalaria, Dr. Miguel Ángel Calleja, former […]

Japan’s PMDA Evaluates Side Effects of Insulins, Cancer Drugs

Country: JAPAN | Region: ASIA & SOUTH PACIFIC | Type: Regulation | Keywords: #astrazeneca #cancer #elililly #insulin #janssen #novonordisk #pmda #sideeffects PRICENTRIC BRIEF: Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) is currently investigating new side effect risks for 15 insulins and two cancer drugs The PMDA is examining risks associated with Eli Lilly’s Humalog/Lyumjev (insulin lispro) and Novo Nordisk’s Xultophy (insulin degludec + liraglutide) and Fiasp (insulin aspart) Also under review […]

EVERSANA™ appoints seasoned oncology veteran Suzanne Greenwood to commercial leadership team

Chicago– October 24, 2019 – EVERSANATM, the leading independent provider of global commercial services to the life sciences industry, today appointed oncology veteran Suzanne Greenwood, RN, BSN, to Senior Vice President, Commercial Solutions. Greenwood joins EVERSANA after more than three decades at leading clinical and pharmaceutical manufacturers, distributors, and technology companies, including Bristol-Myers Squibb, McKesson, […]